These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 26758077

  • 1. Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.
    Ebbers HC, Chamberlain P.
    BioDrugs; 2016 Feb; 30(1):1-8. PubMed ID: 26758077
    [Abstract] [Full Text] [Related]

  • 2. Global regulatory standards for the approval of biosimilars.
    Mounho B, Phillips A, Holcombe K, Grampp G, Lubiniecki T, Mollerup I, Jones C.
    Food Drug Law J; 2010 Feb; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Biosimilar regulation in the EU.
    Kurki P, Ekman N.
    Expert Rev Clin Pharmacol; 2015 Feb; 8(5):649-59. PubMed ID: 26294076
    [Abstract] [Full Text] [Related]

  • 5. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
    Ogura M, Coiffier B, Kwon HC, Yoon SW.
    Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
    Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I.
    Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
    [Abstract] [Full Text] [Related]

  • 10. [The story of biosimilars--chance or threat?].
    Woroń J, Kocić I.
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [Abstract] [Full Text] [Related]

  • 11. The Regulation of Biosimilars in Latin America.
    Garcia R, Araujo DV.
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [Abstract] [Full Text] [Related]

  • 12. Biosimilar: what it is not.
    de Mora F.
    Br J Clin Pharmacol; 2015 Nov; 80(5):949-56. PubMed ID: 25865457
    [Abstract] [Full Text] [Related]

  • 13. Biosimilars: Here and Now.
    Lemery SJ, Esteva FJ, Weise M.
    Am Soc Clin Oncol Educ Book; 2016 Nov; 35():e151-7. PubMed ID: 27249717
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biosimilar medicines - Review.
    Dos Reis C, Teixo R, Mendes F, Cruz RS.
    Int J Risk Saf Med; 2016 Mar 16; 28(1):45-60. PubMed ID: 27176756
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
    Peeters M, Lipp HP, Park M, Yoon YC, Arnold D.
    Future Oncol; 2023 Feb 16; 19(6):427-450. PubMed ID: 36883661
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biosimilars: in support of extrapolation of indications.
    Ebbers HC.
    J Crohns Colitis; 2014 May 16; 8(5):431-5. PubMed ID: 24594005
    [Abstract] [Full Text] [Related]

  • 20. The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary?
    McCamish M, Woollett G.
    Clin Pharmacol Ther; 2013 Apr 16; 93(4):315-7. PubMed ID: 23443756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.